Jeroen Jansen, PhD
Scientific Advisor, PHE
Vice President, Chief Scientist, Evidence Synthesis and Decision Modeling, Precision Xtract
In addition to his role as Scientific Advisor at PHE and Chief Scientist, Evidence Synthesis and Decision Modeling at Precision Xtract, Dr. Jansen is an Adjunct Professor of Health Research & Policy (Epidemiology) at Stanford University and Lead Scientific Advisor – Open Source Value Project (OSVP) at the Innovation and Value Initiative (IVI), where he oversees the development of open-source cost-effectiveness models. He has 15 years of research experience in the areas of evidence synthesis and economic modeling. He was an associate editor of Research Synthesis Methods and is co-author of a textbook on network meta-analysis for decision-making. Dr. Jansen has published extensively on both applied and methods research in his areas of expertise. Notable contributions are the development of guidance for consumers and producers of network meta-analysis studies (ISPOR, PRISMA), as well as the development of methods for network meta-analysis of time-to-event data, repeated measures, and integration of patient level data with study level data. Previously, he was a founder of Redwood Outcomes, a health economics and outcomes research firm that was acquired by the Precision Medicine Group.
PhD, Epidemiology, Erasmus University
MSc, Vrije Universiteit
- Hutton B, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015.
- Jansen JP, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014.
- Jansen JP. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value Health. 2011.
- Johnston BC, et al. Comparison of weight loss among named diet programs in overweight adults: a meta-analysis. JAMA. 2014.
- Van der Valk ME, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 2014.